Indocollyre

Indometacin, the active ingredient in Indocollyre, is a non‑steroidal anti‑inflammatory drug presented as an ophthalmic solution for ocular use. It reduces inflammation and pain in the eye by inhibiting prostaglandin synthesis, making it useful after surgery or in inflammatory eye conditions.

GNH USA supplies Indocollyre as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Indometacin ophthalmic solution is employed to manage ocular inflammation and related discomfort. It acts locally to control prostaglandin‑mediated processes in the eye.

- Post‑operative ocular inflammation: reduces swelling and pain after eye surgery. - Anterior uveitis: helps control intra‑ocular inflammation and discomfort. - Allergic conjunctivitis: alleviates redness, itching and swelling caused by allergic reactions.

Indometacin ophthalmic solution may cause local adverse reactions.

Common Side Effects: - Stinging or burning sensation upon instillation. - Transient blurred vision. - Increased tearing or watery discharge. - Conjunctival hyperemia (redness). - Mild ocular irritation.

Serious or Rare Side Effects: - Corneal epithelial defects or ulceration. - Persistent intra‑ocular pressure elevation. - Severe allergic reaction (e.g., angio‑edema of the eyelid). - Vision loss due to corneal toxicity. - Endophthalmitis (infection inside the eye).

Before using Indocollyre, consider the following safety measures.

- Allergy assessment: avoid if known hypersensitivity to indometacin or other NSAIDs. - Corneal health: do not use in patients with active corneal epithelial defects. - Intra‑ocular pressure: monitor patients with glaucoma or ocular hypertension. - Systemic NSAID use: limit concurrent systemic NSAIDs to reduce systemic exposure. - Pregnancy and lactation: use only if clearly needed and prescribed by a specialist. - Store at room temperature: keep in the original container, protect from light and moisture.

Indometacin ophthalmic solution can interact with other medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Systemic anticoagulants (e.g., warfarin): increased risk of bleeding. - Systemic corticosteroids: heightened risk of ocular complications. - Other topical NSAIDs: additive toxicity to corneal epithelium.

Moderate Interactions (Monitor Closely): - Systemic NSAIDs: potential for cumulative prostaglandin inhibition. - Beta‑blocker eye drops: possible additive reduction in intra‑ocular pressure. - Anticholinergic eye drops: may affect tear film stability.